Giampietro, Antonella
 Distribuzione geografica
Continente #
EU - Europa 2.608
NA - Nord America 2.452
AS - Asia 1.020
SA - Sud America 219
AF - Africa 30
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 2
Totale 6.336
Nazione #
US - Stati Uniti d'America 2.424
DE - Germania 1.036
SE - Svezia 409
SG - Singapore 382
CN - Cina 362
IT - Italia 335
BR - Brasile 199
UA - Ucraina 177
FR - Francia 133
IE - Irlanda 118
GB - Regno Unito 85
ID - Indonesia 84
RU - Federazione Russa 74
FI - Finlandia 71
IN - India 61
PL - Polonia 61
BE - Belgio 25
NL - Olanda 25
HK - Hong Kong 22
CA - Canada 21
KR - Corea 18
TR - Turchia 17
AT - Austria 16
IR - Iran 14
JP - Giappone 14
CI - Costa d'Avorio 9
VN - Vietnam 8
CZ - Repubblica Ceca 7
ES - Italia 7
LK - Sri Lanka 6
ZA - Sudafrica 6
AR - Argentina 5
CO - Colombia 5
EG - Egitto 4
IQ - Iraq 4
MA - Marocco 4
MX - Messico 4
PK - Pakistan 4
PT - Portogallo 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
AZ - Azerbaigian 3
BG - Bulgaria 3
CH - Svizzera 3
EC - Ecuador 3
EU - Europa 3
MD - Moldavia 3
PE - Perù 3
RO - Romania 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
BY - Bielorussia 2
CR - Costa Rica 2
GH - Ghana 2
GR - Grecia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
PY - Paraguay 2
UZ - Uzbekistan 2
VE - Venezuela 2
AU - Australia 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
BH - Bahrain 1
BW - Botswana 1
DK - Danimarca 1
GE - Georgia 1
GU - Guam 1
HU - Ungheria 1
IL - Israele 1
JM - Giamaica 1
JO - Giordania 1
KE - Kenya 1
KW - Kuwait 1
LI - Liechtenstein 1
NG - Nigeria 1
NO - Norvegia 1
NP - Nepal 1
OM - Oman 1
RS - Serbia 1
SA - Arabia Saudita 1
SC - Seychelles 1
TH - Thailandia 1
TN - Tunisia 1
Totale 6.336
Città #
Chandler 582
Singapore 250
Ashburn 135
New York 114
Dublin 110
San Mateo 108
Rome 87
Ann Arbor 82
Jakarta 81
Jacksonville 72
Fairfield 68
Wilmington 68
Marseille 61
Milan 56
Boston 55
Nürnberg 55
Warsaw 55
Nanjing 48
Moscow 47
The Dalles 45
Bremen 44
Los Angeles 44
Seattle 41
Cattolica 40
Princeton 40
Dearborn 34
Munich 32
Houston 31
Redwood City 31
Helsinki 30
Woodbridge 29
Brussels 24
Nanchang 24
Cambridge 23
Shanghai 23
Beijing 21
Hangzhou 21
Lawrence 21
Boardman 20
Hong Kong 20
Mountain View 20
Zhengzhou 19
Frankfurt am Main 18
Chicago 17
Hefei 17
Hyderabad 17
University Park 17
Nuremberg 16
North Bergen 15
Seoul 15
Shenyang 15
Fremont 14
Guangzhou 13
London 13
Düsseldorf 12
Norwalk 12
Augusta 11
Kunming 11
Leawood 11
Vienna 11
Hebei 10
Izmir 10
São Paulo 10
Abidjan 9
Kish 9
Lauterbourg 9
Portsmouth 9
Redmond 9
Turku 9
Changsha 8
Lancaster 8
Mumbai 8
Santa Clara 8
Brescia 7
Piacenza 7
Pune 7
Tianjin 7
Toronto 7
Washington 7
Andover 6
Belo Horizonte 6
Canterbury 6
Jiaxing 6
Paris 6
Rio de Janeiro 6
West Jordan 6
Amsterdam 5
Brooklyn 5
Colombo 5
Hanoi 5
Menlo Park 5
Montreal 5
Renton 5
Campobasso 4
Cornaredo 4
Des Moines 4
Falkenstein 4
Monmouth Junction 4
Palermo 4
Phoenix 4
Totale 3.329
Nome #
Hypophysitis Outcome and Factors Predicting Responsiveness to Glucocorticoid Therapy: A Prospective and Double-Arm Study. 244
Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review 240
Double pituitary adenomas 199
Coenzyme Q10 evaluation in pituitary-adrenal axis disease: preliminary data. 162
Male fertility and reduction in semen parameters: A single tertiary-care center experience 158
Role of a mini-invasive approach in the diagnosis and treatment of tubo-peritoneal infertility as an altenative to IVF [Il ruolo di un approccio chirurgico mini-invasivo nella diagnosi e trattamento della sterilità tubo-peritoneale in alternativa alla FIVET] 154
Typical and Atypical Pituitary Adenomas: A Single-Center Analysis of Outcome and Prognosis 154
Non Alcoholic Fatty Liver Disease is Associated with Increased GHBP and Reduced GH/IGF-I Levels 150
Effects of gherlin administration on endocrine and metabolic parameters in obese women with polycystic ovary syndrome 142
Circulating endothelial cells as marker of endothelial damage in male hypogonadism 140
An Overview of Diagnosis of Primary Autoimmune Hypophysitis in a Single Prospective Monocentric Experience 140
NOVEL BIOMARKERS OF ANDROGEN DEFICIENCY FROM SEMINAL PLASMA PROFILING USING HIGH-RESOLUTION MASS SPECTROMETRY. 135
Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study 129
Isolated growth hormone deficiency: clinical entity? 122
Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGF-I levels 115
Circulating endothelial cells as marker of endothelial damage in male hypogonadism 114
Influence of diabetes mellitus on vertebral fractures in men with acromegaly 111
Effects of ghrelin administration on endocrine and metabolic parameters in obese women with polycystic ovary syndrome 108
Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency 108
Radically resected pituitary adenomas: prognostic role of Ki67 labeling index in monocentric retrospective series and literature review 106
The Changing Clinical Spectrum of Hypophysitis 104
The effect of treatment with growth hormone on fertility outcome in eugonadal women with growth hormone deficiency: report of four cases and review of the literature 102
Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes 101
Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: An immunohistochemical study 101
Significant GH-deficiency after long-term cure by surgery in adult patients with Cushing s disease 99
Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response 99
Fertility and hypopituitarism 96
GH receptor isoforms and skeletal fragility in acromegaly 93
Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second Line Therapies: A Longitudinal Study 93
DIAGNOSIS OF ENDOCRINE DISEASE: Primary Empty Sella: a comprehensive review 84
Synchronous Bilateral Adrenalectomy in ACTH-dependent Hypercortisolism: Predictors, Biomarkers and Outcomes 78
Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. 77
Characteristics and outcomes of Italian patients from the observational, multicentre, hypopituitary control and complications study (HypoCCS) according to tertiles of growth hormone peak concentration following stimulation testing at study entry 76
Quantitative Analysis of the Seminal Plasma Proteome in Secondary Hypogonadism 75
The changing clinical spectrum of endocrine adverse events in cancer immunotherapy 71
Empty sella syndrome: Multiple endocrine disorders. 70
Human leucocyte antigens coeliac haplotypes and primary autoimmune hypophysitis in caucasian patients 69
Galectin-3 and Estrogen Receptor Alpha as Prognostic Markers in Prolactinoma: Preliminary Results From a Pilot Study 69
Vertebral fractures in patients with acromegaly: a 3-year prospective study 68
Clinical management of teratoma, a rare hypothalamic-pituitary neoplasia 67
Reappraising the Role of Trans-Sphenoidal Surgery in Prolactin-Secreting Pituitary Tumors. 67
The Role of Growth Hormone Receptor Isoforms and Their Effects in Bone Metabolism and Skeletal Fragility 67
Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study 65
Neuro-radiological features can predict hypopituitarism in primary autoimmune hypophysitis 65
Effects of Pegvisomant and Pasireotide LAR on Vertebral Fractures in Acromegaly Resistant to First-generation SRLs. 64
First Case of Mature Teratoma and Yolk Sac Testis Tumor Associated to Inherited MEN-1 Syndrome. 61
Growth hormone receptor isoforms and fracture risk in adult-onset growth hormone-deficient patients. 60
Understanding the effect of acromegaly on the human skeleton. 60
Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours 60
Autoantibody reactivity profile of primary autoimmune hypophysitis patients: preliminary results 60
Short- and long-term responsiveness to low dose growth hormone (GH) in adult GH deficiency: Role of GH receptor polymorphism. 57
Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant 57
Solitary Metastatic Melanoma of the Pituitary Gland: Report of Two Cases and Literature Review 56
Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly. 56
Pituitary Enlargement and Hypopituitarism in Patients Treated with Immune Checkpoint Inhibitors: Two Sides of the Same Coin? 54
Pancreas as an Unusual Metastatic Site of Medullary Thyroid Carcinoma: A Case of Very Long-term Follow-up Under Prolonged Treatment with Somatostatin Analogues 51
Multidimensional geriatric evaluation in acromegaly: a comparative cross-sectional study 51
Prevalence of morphometric vertebral fractures in "difficult" patients with acromegaly with different biochemical outcomes after multimodal treatment. 50
The Pathogenic RET Val804Met Variant in Acromegaly: A New Clinical Phenotype? 50
Acromegaly can be cured by first-line pasireotide treatment? 49
Acromegaly in the elderly patients 49
Hypothalamitis and pituitary atrophy 49
Bone safety of dual-release hydrocortisone in patients with hypopituitarism. 44
Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in Acromegaly) Study 41
Aggressive PitNETs and Potential Target Therapies: A Systematic Review of Molecular and Genetic Pathways 40
Systemic comorbidities of acromegaly in real-life experience: which difference among young and elderly patients? 35
Unveiling the Etiopathogenic Spectrum of Hypophysitis: A Narrative Review 34
The multi-biomarker acro-TIME score predicts fg-SRLs response: preliminary results of a retrospective acromegaly cohort 31
Multidisciplinary management of difficult/aggressive growth-hormone pituitary neuro-endocrine tumors 30
Colon Cancer Presenting as Pituitary Mass and Hypopituitarism: Recognition and Multidisciplinary Approach of a Rare Case 28
CD68+ and CD8+ immune cells are associated with the growth pattern of somatotroph tumors and response to first generation somatostatin analogs 26
Trouillas’s Grading and Post-Surgical Tumor Residue Assessment in Pituitary Adenomas: The Importance of the Multidisciplinary Approach 25
De-escalation treatment with pasireotide for acromegaly: a long-term experience 25
Trouillas's Grading and Post-Surgical Tumor Residue Assessment in Pituitary Adenomas: The Importance of the Multidisciplinary Approach 24
Psychological complications in patients with acromegaly: relationships with sex, arthropathy, and quality of life 23
Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours 22
Bone health and skeletal fragility in second- and third-line medical therapies for acromegaly: preliminary results from a pilot single center experience 19
Cholecalciferol Use Is Associated With a Decreased Risk of Incident Morphometric Vertebral Fractures in Acromegaly 19
Markers of humoral and cell-mediated immune response in primary autoimmune hypophysitis: a pilot study 18
Second line treatment of acromegaly: Pasireotide or Pegvisomant? 17
Impact of the diagnostic delay of acromegaly on bone health: data from a real life and long term follow-up experience 14
Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response 11
Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly 11
Use of 111In-pentetreotide scintigraphy for diagnosis and management of resistant macroprolactinoma 10
Effects of glucocorticoid replacement therapy in patients with pituitary disease: A new perspective for personalized replacement therapy 8
Tumor features in adult papillary and adamantinomatous craniopharyngioma: neuroradiological evaluation of pituitary-hypothalamic-axis dysfunction and outcome prediction 5
null 4
Totale 6.445
Categoria #
all - tutte 29.663
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.663


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202099 0 0 0 0 0 0 0 0 0 0 67 32
2020/2021419 20 42 11 42 50 27 47 9 43 55 68 5
2021/2022617 30 33 7 47 74 27 10 112 28 26 85 138
2022/20231.516 173 207 123 252 80 211 89 127 157 13 53 31
2023/2024717 32 160 17 32 31 142 35 8 28 34 93 105
2024/20251.352 30 40 124 75 101 74 37 67 273 188 343 0
Totale 6.445